|
|
|
|
|
|
|
Highlights from the 2023 American Urological Association Annual Meeting |
|
|
|
|
|
Society of Urologic Oncology
|
|
| Management of Metastatic Non-Clear Cell RCC
|
| Brian Rini, MD, FASCO
|
| Brian Rini gave a presentation focusing on the management of metastatic non-clear cell renal cell carcinoma (nccRCC). First, he focused on papillary renal cell carcinoma (RCC). Non clear-cell RCC is a mixed bag of histologies, biologies, and responses to therapy. VEGF and mTOR targeted therapy have minimal (but not 0!) activity as monotherapy.
|
|
|
|
|
|
| The Role of Cytoreductive Partial Nephrectomy
|
| Ithaar Derweesh, MD |
| Ithaar Derweesh presents the role of cytoreductive partial nephrectomy in the setting of metastatic renal cell carcinoma. He does this through the context of a case presentation. In an era characterized by more effective systemic therapies with better oncologic outcomes (and longer survival), CPN for imperative indications is safe and feasible for larger and complex renal masses. Long-term impact of functional decline in metastatic patients is not characterized.
|
|
|
|
|
|
| Surgical Complications after Robotic Partial Nephrectomy |
| Alexander Kutikov, MD, FACS |
| Alexander Kutikov lead a talk on the surgical complications associated with Robotic Partial Nephrectomy. He starts by highlighting a collaborative review he and I worked on for European Urology that walks through decision making for the management of localized solid renal masses – where a key decision point is the choice to treat the tumor, and at which point, we have to choose between radical nephrectomy, partial nephrectomy, and ablative options. |
|
|
|
|
|
|
|
|
|
|
| Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer |
| Srikala Sridhar, MD, MSc, FRCSC |
In this presentation, Srikala Sridhar gave a talk on the role of neoadjuvant immunotherapy for muscle-invasive bladder cancer. IO therapies have significantly changed the landscape. They are already approved in the NMIBC, adjuvant, and first/late-stage metastatic urothelial carcinoma settings. The only setting they have not yet been approved for is in the neoadjuvant setting.
|
|
|
|
|
|
| Optimizing Care of Bladder Cancer in Women |
| Katie S. Murray, DO |
| Katie Murray presents the optimization of care of bladder cancer in women. The topic is broader than just the optimization of care. She notes that there are significant gender disparities that need to be addressed, but she also focuses on organ-sparing cystectomy, vaginal wall-sparing cystectomy, and sexual function after cystectomy. |
|
|
|
|
|
| Debate: Renaming Gleason 6 Prostate Cancer
|
| Matthew R. Cooperberg, MD, MPH and William Catalona, MD
|
| In this presentation regarding the renaming of Gleason 6 Prostate Cancer, William Catalona started the debate with the CON side of the, while Dr. Matthew Cooperberg followed with the PRO. GG1 is an exceptionally common feature of aging, and in 2023 nearly universally represents overdiagnosis, effectively an incidental adverse effect of screening intending to find GG >= 2 cancers. It is argued that this change would dramatically improve the benefit to harm ratio for screening, and likely improve primary care uptake of screening, with mortality benefits far more than outweighing missed progression events.
|
|
|
|
|
|
|
|
|
|
|
| Updates on Clinical Trials in Prostate Cancer
|
| Russel Szmulewitz, MD |
| Russel Szmulewitz provides an update on clinical trials in prostate cancer. He started by highlighting the clinical states of prostate cancer, beginning in the non-castrate clinically localized setting and extending to the late stage metastatic castration resistant prostate cancer.
|
|
|
|
|
|
| New Guidelines for Sexual Health Care with Prostate Cancer |
| Daniela Wittmann, Ph.D., LMSW |
| Daniela Wittman gave a summary of new guidelines from an international panel on sexual health care for prostate cancer patients. As background, she notes that sexual dysfunction is the most commonly reported health related quality of life outcome following therapies for prostate cancer, affecting men, partners, and their relationships. |
|
|
|
|
|
|
|
|
|
|
|
